Arcara Jeffrey bought 497 shares of Corvus Pharmaceuticals, Inc. at $11.12 for $5.52k on Nov 12, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Business Officer
Chief Business Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$5,524.16Shares × reported price
Shares traded
497Common Stock
Price per share
$11.12Reported price. Read footnotes for ranges.
% of reported position traded
16.57%This security and ownership context
Holdings after
3,497Direct
Trade date
Nov 12, 2026Buy
Filed
Nov 13, 2026, 5:54 PM ET1-day reporting delay
Accession
0001610717-26-000454Code P · Transaction 401194
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 3,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Buy3,000$11.46$34,380.60Trade 401193
Nov 13, 2026Buy503$10.37$5,216.11Trade 401195
Nov 13, 2026Buy500$10.71$5,354.35Trade 401196
4 transaction rows in this filing. Joint filers share the same rows.

CRVS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CRVS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

No footnotes recorded. Check the original SEC filing for the complete report.